CareLit Fachartikel
The Proteasome Inhibitor Bortezomib and Oncolytic Virotherapy act synergistically in hepatocellular carcinoma
B Boozari, TC Wirth, N Woller, MP Manns, S Kubicka, F Kühnel · Zeitschrift für Gastroenterologie · 2008 · Heft 01
Dokument
1106886
CareLit-ID
Jahr
2008
Publikation
PDF
nein
Metadaten
DOI
ja
zitierfähig
Bibliografische Angaben
Zusammenfassung
Oncolytic Therapy using conditionally replicating adenoviral vectors provides a challenging tool for the treatment of solid tumors. Recently, the proteasome inhibitor Bortezomib has been established as novel anti-cancer agent. However, exact molecular mechanisms of Bortezomib induced cell death are not fully understood and potential interference with virotherapy if applied as combination treatment is unkown. Aim of this work was to investigate adenoviral replication under Bortezomib treatment in Huh–7 cells. Huh–7 cells were treated with single or combined treaments of Bortezomib (10 nM) and hTERT-Ad virotherapy…
Schlagworte
Bortezomib
Caspase 3
Apoptosis
Observation
Autophagy
Work
Zeitschrift für Gastroenterologie
